Optimizing the Management of Community-Acquired Pneumonia in Hospitalized Patients on the Basis of Modifiable Factors

Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(2):183-188

Type
Journal article

Abstract

Choice of empiric therapy should be based on complex of data on etiology and local antimicrobial resistance trends as well as on clinical-economic analysis. According to our results, from the pharmacoeconomic point of view the most optimal agents for the treatment of communityacquired pneumonia in low-risk hospitalized patients are aminopenicillins, in high-risk patients – combination of anti-pneumococcal β-lactam agent (preferably cefotaxime or ceftriaxone) with i.v. macrolide (e.g. azithromycin).

Views
0 Abstract
0 PDF
0 Crossref citations
Shared